New Survey Highlights Gap Between Perceived AI Readiness And Tested Disaster Recovery Capability 
Syngenta Deploys Tetra OS to Accelerate Scientific Discovery Through Industrial-Scale Data Automation UM171 cell therapy demonstrates improved outcomes compared to cord and matched unrelated donor peripheral blood transplants in real-world setting
MONTRÉAL, Dec. 12, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood…
Genmab to Hold 2022 R&D Update and ASH Data Review Meeting
Media Release Event to be held live in New Orleans, Louisiana Meeting to be webcast…
(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a…
Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
Study met the primary endpoint and key secondary endpoints, consistent with positive topline results from…
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
Funding Demonstrates Importance of Working with Private Sector to Improve Lives of Marylanders, says Governor…
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
– $30M Series A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and NEW YORK,…
Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date
BMF-500, an investigational third generation covalent FLT3 inhibitor, demonstrated preclinically: Picomolar affinity to activating FLT3…
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) — Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company…
VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event
BRIDGEWATER, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or…
Recce Pharmaceuticals Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE® 327 in Patients with Diabetic Foot Infections
Highlights: Phase 1/2 trial of RECCE® 327 (R327) is approved to start at the South…
ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing
LOS ANGELES, CA, Dec. 12, 2022 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,…
UPDATE — Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) — Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or…
First Wave BioPharma to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2023”
BOCA RATON, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (NASDAQ: FWBI)…
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical…
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers…
Genomic Biopharma and patient advocacy organization POIC e dintorni APS partner to offer whole genome sequencing to bring better treatments and cures to those living with gastrointestinal diseases
L’AQUILA, Italy, Dec. 12, 2022 (GLOBE NEWSWIRE) — Genomic Biopharma Inc., a genomic medicine-based drug…
BiondVax Regains Nasdaq Compliance
JERUSALEM, Dec. 12, 2022 (GLOBE NEWSWIRE) — via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)…
Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA
All patients achieved sustained engraftment and supraphysiological SGSH enzyme levels with median 1.5 years follow-up…
IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100
Results from the first cohort of patients with hematological malignancies show patients remained progression free;…
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…